Proceedings of the International scientific and practical conference ―Oxford International Science Forum‖ (February 6-8, 2026) / Publisher website: www.naukainfo.com. - Oxford, United Kingdom, 2026. - 245 p.

192 weeks prior to implant placement contributes to improved vascular response, reduced inflammatory markers, and enhanced osseointegration potential. Discussion. The findings confirm that nicotine exposure represents a critical biological risk factor for implant therapy irrespective of the method of consumption. While alternative nicotine products eliminate combustion-related toxins, nicotine-mediated vasoconstriction, impaired angiogenesis, and immune dysregulation persist. These mechanisms explain the continued susceptibility to peri-implantitis and marginal bone loss in users of non-combustible tobacco products. From a clinical perspective, implant placement in active smokers should be classified as a high-risk procedure. Comprehensive risk assessment, patient education, smoking cessation counseling, and modification of surgical and prosthetic protocols are essential components of successful treatment planning. Conclusions. Tobacco use significantly compromises dental implant outcomes by increasing the risk of peri-implant inflammation, marginal bone loss, and implant failure. Conventional cigarette smoking poses the highest level of risk; however, alternative nicotine delivery systems cannot be considered biologically safe in implant dentistry. Complete smoking cessation remains the most effective preventive strategy. In patients unable or unwilling to quit nicotine use, individualized risk-oriented protocols—including intensified professional hygiene, shortened maintenance intervals, and strict peri-implant monitoring—are mandatory to improve long-term treatment success (Figure 1).